Hematologic cancer therapies
This report aims to quantify the trends around the availability and use of therapies for hematological malignancies across selected countries (including the United Kingdom) with reported oncology therapy access challenges and disparities. Trends in overall regulatory approvals, health technology assessments, reimbursement, and final therapy usage have been analysed for drugs indicated in hematological malignancies. Free registration is required to access this report.